SHIP cluster U-turns on Lucentis policy after price is slashed


A primary care trust cluster under the threat of legal action for recommending the use of an unlicensed drug has revoked the policy after the pharmaceutical company cut the price of the medicine.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here